Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis
<b><i>Background:</i></b> Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung function decline. <b><i>Objective:</i></b> To evaluate the results of a lar...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 20, 2016
|
| In: |
Respiration
Year: 2016, Volume: 92, Issue: 2, Pages: 98-106 |
| ISSN: | 1423-0356 |
| DOI: | 10.1159/000448288 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000448288 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/448288 
|
| Author Notes: | Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J. Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse, on behalf of the German Nintedanib Compassionate Use Consortium |
| Summary: | <b><i>Background:</i></b> Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung function decline. <b><i>Objective:</i></b> To evaluate the results of a large cohort of IPF patients treated with nintedanib within a compassionate use program (CUP) in Germany (9 centers). <b><i>Methods:</i></b> Patients (≥40 years) were required to have a confirmed diagnosis of IPF, a forced vital capacity (FVC) ≥50% predicted (pred.) and a carbon monoxide diffusing capacity (D<smlcap>LCO</smlcap>) 30-79% pred. and not to be eligible for pirfenidone treatment. Clinical data, pulmonary function tests and adverse events were recorded up to July 2015. <b><i>Results:</i></b> Sixty-two patients (48 male/14 female) with moderate IPF (FVC 64 ± 17% pred. and D<smlcap>LCO</smlcap> 40 ± 10% pred.) were treated with nintedanib. 77% of patients switched from pirfenidone (mean treatment duration 14 ± 2 months) mostly due to disease progression (mean decline in FVC 7.4 ± 3% pred. in the 6 months prior to nintedanib intake). Initiation of nintedanib treatment occurred 69 ± 29 months after IPF diagnosis, and mean treatment duration was 8 ± 4 months. Most patients (63%) stabilized 6 months after treatment start (mean FVC decline 3 ± 1 vs. -17 ± 2% in patients with disease progression; p < 0.01). The most common adverse events were diarrhea (63%) and weight loss (50%). Dose reduction occurred in 34% of cases and treatment discontinuation in 10%. <b><i>Conclusion:</i></b> Nintedanib treatment was generally well tolerated and was associated with FVC stabilization in the majority of IPF patients in this CUP setting where most patients were not treatment naïve. Our data are in agreement with the previously published data. |
|---|---|
| Item Description: | Gesehen am 14.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1423-0356 |
| DOI: | 10.1159/000448288 |